Dis-CoV-er

• Research type

  Research Study

• Full title

  Dis-CoV-er: Developing a COVID-19 risk stratification tool for cancer patients based on an investigation of SARS-CoV-2 exposure and handling.

• IRAS ID

  285060

• Contact name

  Nagesh Kalakonda

• Contact email

  nageshk@liverpool.ac.uk

• Sponsor organisation

  Clatterbridge Cancer Centre

• Duration of Study in the UK

  1 years, 2 months, 0 days

• Research summary

  Research Summary
  The emergence and establishment of the COVID-19 pandemic and ‘social-distancing’ and ‘travel restriction’ measures are impacting delivery of cancer care, treatment decisions and outcomes. To understand the true impact of the pandemic a more comprehensive testing strategy 1) to establish infection rates and 2) assessment of immunological responses to viral exposure is essential.
  Patients attending hospitals (CCC and CH) for essential inpatient, outpatient, day care or treatment episodes whose SARS-CoV-2 infection status is unknown or previously negative will be invited to participate in this study. Viral swabs and blood samples will be obtained at presentation and after an interval. The samples will be biobanked and analysed at the end of the recruitment period (1000 patients; 6 – 10 weeks). Consent will be sought for access to anonymised demographic and clinical data to draw conclusions regarding exposure, susceptibility, and immune responses to SARS-CoV-2 and associated risk factors.

  Summary of Results
  No Lay Summary of results has been prepared

• REC name

  East of England - Essex Research Ethics Committee

• REC reference

  20/EE/0171

• Date of REC Opinion

  22 Jul 2020

• REC opinion

  Further Information Favourable Opinion